Skip to main content
. 2020 Mar 31;16:881–890. doi: 10.2147/NDT.S246136

Table 2.

Comparison of Remitters vs Non-Remittors

Variables Total Non-Remitters Remitters p value
N 3130 1823 1307
Age of onset (years): mean±SD 34.7±12.5 33.5±12.0 36.2±13.0 <0.001
Personality disorders: n (%) 181 (5.8) 148 (8.1) 32 (2.4) <0.001
Pervasive developmental disorders: n (%) 207 (6.6) 148 (8.1) 59 (4.5) <0.001
Alcohol/substance abuse: n (%) 167 (5.3) 133 (7.3) 34 (2.6) <0.001
Physical comorbidity: n (%) 968 (30.9) 557 (30.6) 411 (31.4) 0.601
Rapid cycling: n (%) 329 (10.5) 264 (14.5) 65 (5.0) <0.001
Social function: n (%) <0.001
 Global Assessment of Functioning 81–100 1008 (32.2) 203 (11.1) 805 (61.6)
 Global Assessment of Functioning 61–80 1407 (45.0) 972 (53.3) 435 (33.3)
 Global Assessment of Functioning 41–60 606 (19.4) 550 (30.2) 56 (4.3)
 Global Assessment of Functioning 1–40 87 (2.8) 81 (4.4) 6 (0.5)
Pharmacological treatment: n (%) 3104 (99.2) 1811 (99.3) 1293 (98.9) 0.147
Mood stabilizers: n (%)
 Lithium 1488 (47.5) 783 (43.0) 705 (53.9) <0.001
 Valproic acid 893 (28.5) 533 (29.2) 358 (27.4) 0.259
 Carbamazepine 149 (4.8) 97 (5.3) 52 (4.0) 0.082
 Lamotrigine 744 (23.8) 481 (26.4) 263 (20.1) <0.001
Antipsychotics: n (%) 1692 (54.1) 1081 (59.3) 611 (46.7) <0.001
Antidepressants: n (%) 1291 (41.2) 828 (45.4) 463 (35.4) <0.001
Anxiolytics: n (%) 1133 (36.2) 739 (40.6) 394 (30.2) <0.001
Hypnotics: n (%) 1886 (60.3) 1213 (66.5) 673 (51.5) <0.001